Novartis

News

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

Novartis puts up $1.7bn for Voyager's gene therapy platform

Voyager Therapeutics has signed another big pharma partner for its TRACER adeno-associated virus (AAV) vector technology, designed to improve the safety of gene therapies, with Novartis tak

News

Jardiance pulls ahead of Forxiga with heart failure approval...

Boehringer Ingelheim and Eli Lilly's SGLT2 inhibitor Jardiance has become the first drug in the class to be approved in the EU for all adults with symptomatic chronic heart failure (CHF), g

News

Dupixent falls short in phase 3 chronic spontaneous urticari...

Sanofi and Regeneron have reported disappointing results in a trial of Dupixent in people with chronic spontaneous urticaria (CSU) who don't respond to the only approved biologic treatment,

News

No news anytime soon on Sandoz sale, says Novartis

Novartis chief executive Vas Narasimhan has downplayed any chances of swift decision on the future of its generics business Sandoz, saying that a decision on the possible sale of the unit m

News

group of chemical scientists working at the laboratory.

Pharming preps filing for rare disease drug leniolisib after...

Pharming has taken a step closer to getting a second product to market, after its rare disease therapy leniolisib met its objectives in a pivotal trial, setting up regulatory filings in the

News

GSK rejects $68.4bn Unilever bid for consumer health

GlaxoSmithKline (GSK) claims it has rejected three unsolicited, conditional and non-binding proposals from Unilever to acquire GSK Consumer Healthcare in a deal worth approximately $68.4 billion (£

Novartis puts up $1.7bn for Voyager's gene therapy platform

Jardiance pulls ahead of Forxiga with heart failure approval...

Dupixent falls short in phase 3 chronic spontaneous urticari...

No news anytime soon on Sandoz sale, says Novartis

Pharming preps filing for rare disease drug leniolisib after...

GSK rejects $68.4bn Unilever bid for consumer health

Roche's IgAN hopeful sefaxersen passes phase 3 test

Discover a new era of healthcare panel engagement: Grounded ...

Novartis

Editor's Picks